Clusterin expression in malignant lymphomas: A survey of 266 cases

Modern Pathology

Volumn 15, Issue 11, 2002, Pages 1221-1226

  Saffer, Helene ^a   Wahed, Amer ^a   Rassidakis, Georgios Z ^b   Medeiros, L Jeffrey ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; Clusterin; Hodgkin's disease; Immunohistochemistry; Non Hodgkin's lymphoma

Indexed keywords

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER GRADING; CONTROLLED STUDY; HEALTH SURVEY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; T CELL LYMPHOMA; WALDENSTROEM MACROGLOBULINEMIA;

CA-15-3 ANTIGEN; CLUSTERIN; GLYCOPROTEINS; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MOLECULAR CHAPERONES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0036861376     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000036386.87517.AA     Document Type: Article

References (28)

1. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 1983;258:7714-20.
2. Griswold MD, Roberts K, Bishop P. Purification and characterization of a sulfated glycoprotein secreted by Sertoli cells. Biochemistry 1986;25:7265-70.
3. Kirszbaum L, Bozas SE, Walker ID. SP-40, 40, a protein involved in the control of the complement pathway, possesses a unique array of disulfide bridges. FEBS Lett 1992;297:70-6.
4. Rosenberg ME, Silkensen J. Clusterin: Physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
5. Fink TM, Zimmer M, Tschopp J, Etienne J, Jenne DE, Lichter P. Human clusterin (CL1) maps to 8p21 in proximity to the lipoprotein lipase (LPL) gene. Genomics 1993;16:526-8.
6. Purrello M, Bettuzzi S, Di Pietro C, Mirabile E, Di Blasi M, Rimini R, et al. The gene for SP-40, 40, human homologue of rat sulfated glycoprotein 2, rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8. Genomics 1991;10:151-6.
7. Hochgrebe TT, Humphreys D, Wilson R, Easterbrook-Smith SB. A reexamination of the role of clusterin as a complement regulator. Exp Cell Res 1999;249:13-21.
8. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999;274:6875-81.
9. Zwain I, Amato P. Clusterin protects granulosa cells from apoptotic cell death during follicular atresia. Exp Cell Res 2000;257:101-10.
10. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, et al. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000;97:5907-12.
11. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000;157:393-9.
12. Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinomea of the bladder is related to disease progression and recurrence. Urology 2002;59:150-4.
13. Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol 2002;167:703-6.
14. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3:1707-11.
15. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76.
16. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 2000;96:398-404.
17. Ralfkiaer E, Delsol G, Willemze R, Jaffe ES. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of Haematopoietic and Lymphoid Tissues. Pathology and Genetics. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001. pp. 221-4.
18. Rassidakis GZ, Sarris AH, Herling M, Ford RJ, Cabanillas F, McDonnell TJ, et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 2001;159:527-35.
19. Park C-K, Manning JT, Battifora H, Medeiros LJ. Follicle center lymphoma and Warthin tumor involving the same anatomic site: Report of two cases and review of the literature. Am J Clin Pathol 2000;113:113-9.
20. Lin P, Jones D, Dorfman DM, Medeiros LJ. Precursor B-cell lymphoblastic lymphoma: A predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol 2000;24:1480-90.
21. MacLennan KA, Bennett MH, Tu A, Hudson BV, Easerling MJ, Hudson GV, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989;64:1686-93.
22. Aoun P, Greiner TC, Lynch JC, Vose JM, Gordon BG, Chan WC, et al. Clusterin expression is associated with anaplastic large cell lymphoma (ALCL) of T/null cell phenotype with ALK expression [abstract #830]. Mod Pathol 2000;13:142A.
23. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma (ALCL) but fails to differentiate primary from secondary cutaneous ALCL [abstract # 1037]. Mod Pathol 2002;15:249A.
24. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of Haematopoietic and Lymphoid Tissues. Pathology and Genetics. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001, pp. 230-5.
25. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, et al. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998;91:2076-84.
26. Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, et al. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Hematol 2000;109:584-91.
27. Lai R, Medeiros LJ, Dabbagh L, Formenti KS, Coupland RW. Sinusoidal CD30-positive large B-cell lymphoma: A morphologic mimic of anaplastic large cell lymphoma. Mod Pathol 2000;13:223-8.
28. Chittal SM, Caveriviere P, Schwarting R, Gerdes J, Al Saati T, Rigal-Huet F, et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am J Surg Pathol 1988;12:9-21.